U.S. markets closed
  • S&P Futures

    4,551.50
    +7.00 (+0.15%)
     
  • Dow Futures

    35,437.00
    +48.00 (+0.14%)
     
  • Nasdaq Futures

    15,616.50
    +29.25 (+0.19%)
     
  • Russell 2000 Futures

    2,256.70
    +7.20 (+0.32%)
     
  • Crude Oil

    81.80
    -0.86 (-1.04%)
     
  • Gold

    1,796.30
    -2.50 (-0.14%)
     
  • Silver

    24.07
    -0.13 (-0.52%)
     
  • EUR/USD

    1.1597
    -0.0009 (-0.08%)
     
  • 10-Yr Bond

    1.5290
    -0.0900 (-5.56%)
     
  • Vix

    16.98
    +1.00 (+6.26%)
     
  • GBP/USD

    1.3725
    -0.0018 (-0.13%)
     
  • USD/JPY

    113.8540
    +0.0440 (+0.04%)
     
  • BTC-USD

    58,376.86
    -2,320.32 (-3.82%)
     
  • CMC Crypto 200

    1,396.02
    -78.31 (-5.31%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • Nikkei 225

    28,767.87
    -330.37 (-1.14%)
     

Should Value Investors Now Choose Zimmer Biomet (ZBH) Stock?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Zimmer Biomet Holdings, Inc. ZBH stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Zimmer Biomet has a trailing twelve months PE ratio of 24.91, as you can see in the chart below:


 
This level actually compares favorably with the market at large, as the PE for the S&P 500 stands at about 26.47. If we focus on the long-term PE trend, Zimmer Biomet’s current PE level puts it below its midpoint over the past five years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.


 
However, the stock’s PE also compares unfavorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 26.32. At the very least, this indicates that the stock is slightly undervalued right now, compared to its peers.


 
We should also point out that Zimmer Biomet has a forward PE ratio (price relative to this year’s earnings) of just 25.91, so it is fair to expect an increase in the company’s share price in the near future.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Zimmer Biomet has a P/S ratio of about 4.31. This is substantially lower than the S&P 500 average, which comes in at 4.64 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.

Broad Value Outlook

In aggregate, Zimmer Biomet currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Zimmer Biomet a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the P/CF ratio for Zimmer Biomet comes in at 11.2, which is better than the industry average of 21.13. Clearly, ZBH is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Zimmer Biomet might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of C and Momentum Score of B. This gives Zimmer Biomet a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been encouraging. The current quarter estimate witnessed seven upward revisions in the past sixty days compared to four downward revisions, while the current year estimate witnessed 14 upward revisions compared to no downward revision in the same time period.

This has had a noticeable impact on the consensus estimate, as the current quarter consensus estimate improved 6.5% in the past two months, whereas the current year estimate improved 19.1% in the past two months. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Zimmer Biomet Holdings, Inc. Price and Consensus

Zimmer Biomet Holdings, Inc. Price and Consensus
Zimmer Biomet Holdings, Inc. Price and Consensus

Zimmer Biomet Holdings, Inc. price-consensus-chart | Zimmer Biomet Holdings, Inc. Quote

Even with favorable estimate trends, the stock has a Zacks Rank #3 (Hold), which is why we are looking for in-line performance from the company in the near term.

Bottom Line

Zimmer Biomet is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the sector has clearly underperformed the market at large, as you can see below:


 
So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.